- Disease: Post-COVID-19
- Study type: Randomised Clinical Trial
- Study type descriptors: Interventional, Single centre
- Study aim: To demonstrate improvement in physical function measured using the short form-36 health questionnaire in patients with post-COVID-19 syndrome treated with Vericiguat compared with placebo
- Number of participants enrolled: Enrollment data not available
- Study enrolling from to
- Study includes follow-up for 10 weeks
Study Data
- Adults
- General population
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- vasodilator
- Vericiguat
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to